PPARG and neoplasm: Anti-angiogenetic therapy is highly promising since it does not induce aquired anticancer drug resistance.18,19 Drevs et al. demonstrated the effect of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in an animal model of renal cell carcinoma.20 PPAR-γ agonists induce apoptosis in endothelial cells and inhibit vascular endothelial growth factor-induced angiogenesis in rats.